Insulet Corporation
Insulet Corporation (PODD) is a medical‑device company best known for its Omnipod tubeless insulin pump system, aimed at people with type 1 and insulin‑dependent type 2 diabetes. The business model centres on device sales and recurring pod consumables, with supplementary software and services that support automated insulin delivery. With a market capitalisation of roughly $23.2 billion, growth prospects hinge on rising adoption of insulin‑delivery technology, tighter integration with continuous glucose monitoring and expansion into international markets. Key investor considerations include manufacturing scale‑up, reimbursement and regulatory pathways, competition from established pump makers and integrated diabetes platforms, and execution risk around new product roll‑outs. Financial performance can be variable and past performance is not a guarantee of future returns. This is general educational information only and not personal advice; investors should assess suitability for their own circumstances and may wish to consult a regulated financial adviser.
Why It's Moving
Insulet Propels Growth with FDA Enhancements and Leadership Moves, Boosting Revenue Outlook
Insulet (PODD) has gained momentum following FDA clearance of its upgraded Omnipod 5 insulin pump algorithm, which promises improved glucose control for diabetes patients. Coupled with strong sales growth and strategic leadership appointments, the company is raising its 2025 revenue guidance, reflecting robust market demand and innovation leadership.
- FDA 510(k) clearance granted on December 4 for Omnipod 5 enhancements, including a new 100 mg/dL target glucose level and improved Automated Mode, expected to launch in the U.S. in early 2026; real-world data shows notable Time in Range improvements in type 1 and type 2 diabetes patients.
- Insulet increased 2025 revenue growth guidance to 28%–29% in constant currency, citing strong new customer acquisitions in both U.S. and international markets, with anticipated Q3 results to exceed prior guidance of 22%–25%.
- Corporate leadership bolstered by promotion of Eric Benjamin to COO and hiring of Manoj Raghunandanan as Chief Growth Officer, aiming to accelerate growth, new product innovation, and commercial expansion globally.
Insulet Propels Growth with FDA Enhancements and Leadership Moves, Boosting Revenue Outlook
Insulet (PODD) has gained momentum following FDA clearance of its upgraded Omnipod 5 insulin pump algorithm, which promises improved glucose control for diabetes patients. Coupled with strong sales growth and strategic leadership appointments, the company is raising its 2025 revenue guidance, reflecting robust market demand and innovation leadership.
- FDA 510(k) clearance granted on December 4 for Omnipod 5 enhancements, including a new 100 mg/dL target glucose level and improved Automated Mode, expected to launch in the U.S. in early 2026; real-world data shows notable Time in Range improvements in type 1 and type 2 diabetes patients.
- Insulet increased 2025 revenue growth guidance to 28%–29% in constant currency, citing strong new customer acquisitions in both U.S. and international markets, with anticipated Q3 results to exceed prior guidance of 22%–25%.
- Corporate leadership bolstered by promotion of Eric Benjamin to COO and hiring of Manoj Raghunandanan as Chief Growth Officer, aiming to accelerate growth, new product innovation, and commercial expansion globally.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Insulet's stock with a target price of $380.57, indicating growth potential.
Financial Health
Insulet Corporation shows strong revenue and profits, indicating good financial performance overall.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PODD
At-Home Treatment Revolution | FDA Approval Impact
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.
Published: September 1, 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: August 19, 2025
Explore BasketNext-Generation Drug Delivery Systems
This carefully selected group of stocks represents innovative companies revolutionizing how medications are delivered to patients. Handpicked by our professional analysts, these firms are developing technologies that make treatments simpler, more effective, and user-friendly, creating meaningful investment potential in an evolving healthcare landscape.
Published: July 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Growth from Adoption
Increasing uptake of insulin‑delivery technology could drive revenue through devices and recurring pods, though adoption rates and reimbursement vary by market.
International Expansion
Rolling out into new regions offers scale potential, balanced against regulatory approvals, local reimbursement and distribution challenges.
Innovation & Partnerships
Integration with continuous glucose monitors and progress toward automated insulin delivery can be strategic catalysts, yet execution and competition are material risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
